zamtocabtagene autoleucel for the treatment of patients with r/r dlbcl
Published 1 year ago • 168 plays • Length 1:33Download video MP4
Download video MP3
Similar videos
-
2:49
results from the phase iii echo trial of acalabrutinib plus br in mcl
-
1:03
insights into the cartitude-6 trial: rationale and design
-
1:42
insights into the limber‐103 trial
-
3:26
the risk of thrombotic events in patients with mgus: an analysis from the istopmm trial
-
1:43
extended follow-up of the alpine trial: superior outcomes with zanubrutinib in r/r cll/sll
-
1:44
insights into the phase ii tidal study
-
1:12
traverse: acalabrutinib venetoclax and rituximab for treatment-naïve mcl
-
1:44
the impact of acalabrutinib treatment by line of therapy in patients with cll
-
5:19
cramer: this biotech stock could be worth over $100 billion on an fda approval
-
52:16
cum te poate duce educația către performanță: carttitude cu claudiu jijie
-
22:36
dive into digital pathology market
-
2:00
update of a phase i trial investigating lintuzumab-ac225 plus venetoclax in r/r aml
-
1:18
an insight into the challenges in prolonging remission in aml
-
2:23
re-mind2: observational study comparing tafasitamab lenalidomide to available therapies in r/r dlbcl
-
2:34
the effect of dose reduction of talquetamab in patients with r/r mm: results from monumental-1
-
1:34
advances and unmet needs in second-line treatment of dlbcl
-
1:55
the alpine trial shows improved outcomes with zanubrutinib versus ibrutinib in r/r cll
-
1:52
critical insight into therapeutic progress for ctcl
-
1:07
an insight into the pathogenesis of aml
-
1:12
insights into majestec-4: assessing the role of teclistamab as maintenance in patients with myeloma
-
1:53
the current immunotherapeutic landscape for treatment of dlbcl
-
6:05
real-world data on the effect of ibrutinib flexible dosing treatment strategies on ttnt in cll/sll